Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
246 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Wounds - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Wounds - Pipeline Review, H2 2014', provides an overview of the Wounds's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Wounds, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wounds and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Wounds - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Wounds and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Wounds products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Wounds pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Wounds - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Wounds pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Wounds Overview 11 Therapeutics Development 12 Pipeline Products for Wounds - Overview 12 Pipeline Products for Wounds - Comparative Analysis 13 Wounds - Therapeutics under Development by Companies 14 Wounds - Therapeutics under Investigation by Universities/Institutes 20 Wounds - Pipeline Products Glance 22 Late Stage Products 22 Clinical Stage Products 23 Early Stage Products 24 Unknown Stage Products 25 Wounds - Products under Development by Companies 26 Wounds - Products under Investigation by Universities/Institutes 31 Wounds - Companies Involved in Therapeutics Development 33 Advancell 33 Aerpio Therapeutics, Inc. 34 AlgiPharma AS 35 AndroScience Corporation 36 AnGes MG, Inc. 37 APEIRON Biologics AG 38 Apricus Biosciences, Inc. 39 Aridis Pharmaceuticals LLC 40 Beech Tree Labs, Inc. 41 Bio3 Research S.r.l 42 Biotec Pharmacon ASA 43 Birken AG 44 Blueberry Therapeutics Ltd 45 CYATHUS EXQUIRERE PharmaforschungsGmbH 46 Dongkook Pharmaceutical Co., Ltd. 47 Escape Therapeutics, Inc. 48 GangaGen Inc. 49 Garnet BioTherapeutics 50 Gene Signal International SA 51 GliaMed, Inc. 52 HanAll Biopharma Co., Ltd. 53 Hemostemix Ltd 54 Juventas Therapeutics, Inc. 55 Karyopharm Therapeutics, Inc. 56 Kasiak Research Pvt. Ltd. 57 Kuros Biosurgery AG 58 Living Cell Technologies Limited 59 MediWound Ltd. 60 Microbion Corporation 61 miRagen Therapeutics, Inc. 62 Molecular Design International, Inc. 63 Nabriva Therapeutics AG 64 NeoStem, Inc. 65 Neumedicines Inc. 66 Novan, Inc. 67 Nuvo Research Inc. 68 Octapharma AG 69 Omeros Corporation 70 Omnio Healer AB 71 Pacific Northwest Biotechnology, LLC 72 Pergamum AB 73 Pharming Group N.V. 74 Regenics AS 75 RXi Pharmaceuticals Corporation 76 Sanofi 77 Sirnaomics, Inc. 78 Smith & Nephew Plc 79 SomaGenics Inc. 80 Stratatech Corporation 81 Sucampo Pharmaceuticals, Inc. 82 Theravasc, Inc. 83 Thesan Pharmaceuticals, Inc. 84 Tissue Repair Company 85 vida therapeutics inc. 86 Wounds - Therapeutics Assessment 87 Assessment by Monotherapy Products 87 Assessment by Target 88 Assessment by Mechanism of Action 91 Assessment by Route of Administration 94 Assessment by Molecule Type 96 Drug Profiles 98 A-3APO - Drug Profile 98 Adipose Stem Cell Therapy for Skin Wound - Drug Profile 100 AG-30/5C - Drug Profile 101 AKB-4924 - Drug Profile 102 AlloGraf - Drug Profile 103 alprostadil - Drug Profile 104 ANs-31 - Drug Profile 107 APN-201 - Drug Profile 108 Arginine Butyrate - Drug Profile 110 ARN-077 - Drug Profile 111 ASCJ-9 - Drug Profile 112 Autologous Adipose Stem Cell Therapy for Diabetic Chronic Skin Wound - Drug Profile 114 BB-1000 - Drug Profile 115 BC-7013 - Drug Profile 116 BCI - Drug Profile 117 BCP-01 - Drug Profile 118 Bismuth ethanedithiol - Drug Profile 119 BTL-slo - Drug Profile 120 CaTx-II - Drug Profile 121 Cell Therapy for Wounds - Drug Profile 122 chordin - Drug Profile 123 CM-101 - Drug Profile 124 cobiprostone - Drug Profile 126 CR-2016 - Drug Profile 127 CTR-2 - Drug Profile 128 Cyathus-1102-B - Drug Profile 129 Drug for Dermatology and Infectious Diseases - Drug Profile 130 Drug for Wound Healing - Drug Profile 131 Drug to Antagonize Beta 2 Receptor for Wound Healing - Drug Profile 132 Drugs to Activate iRhom2 for Wound Healing and Cancer - Drug Profile 133 Drugs to Agonize c-Met for Wound - Drug Profile 134 Drugs to Inhibit 11beta-HSD1 for Wound Healing - Drug Profile 135 EscharEx - Drug Profile 136 G-10 - Drug Profile 137 GBT-009 - Drug Profile 138 Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile 140 GM-1485 - Drug Profile 141 GS-156 - Drug Profile 143 HL-156Fib - Drug Profile 144 HP-802247 - Drug Profile 145 Human Growth Factor - Drug Profile 146 hVGF - Drug Profile 147 JVS-100 - Drug Profile 148 KUR-213 - Drug Profile 150 LWnt-3a - Drug Profile 151 MDI-301 - Drug Profile 152 Mesenchymal Cells for Wound Care - Drug Profile 153 MGN-4220 - Drug Profile 154 Migration Stimulating Factor - Drug Profile 155 MMP-26051 - Drug Profile 156 MMP-26052 - Drug Profile 157 Monoclonal Antibody Conjugated for Burns and Wounds - Drug Profile 158 NL-005 - Drug Profile 160 NMIL-121 - Drug Profile 161 NTCELL - Drug Profile 163 OleogelS-10 - Drug Profile 165 Oligomer G for Wounds And Burns - Drug Profile 167 Oxo-Foam - Drug Profile 168 P-128 - Drug Profile 169 Panaecin - Drug Profile 170 Peptide for Wounds - Drug Profile 171 perflenapent for wound healing - Drug Profile 172 Perlecan - Drug Profile 173 PGF - Drug Profile 174 Plasminogen (recombinant) - Drug Profile 175 Protein for Hematological Disorders, Dermatology, Shock and Injury - Drug Profile 176 Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders - Drug Profile 177 Protein to Inhibit SEB and TSST-1 for Infectious Disease, Dermatology, Toxic Shock and Respiratory Disorders - Drug Profile 178 PXL-181 - Drug Profile 179 Recombinant Erythropoetin For Wounds and Bone Regeneration - Drug Profile 180 Recombinant Human Collagen Type 1 - Drug Profile 181 Recombinant Protein for Wounds - Drug Profile 182 Recombinant Protein to Inhibit Granzyme B for Cardiovascular and Dermatology Diseases - Drug Profile 183 Refaheal - Drug Profile 184 RNAi Oligonucleotide for Wound Healing - Drug Profile 185 RNAi Oligonucleotide to Inhibit Fidgetin-like 2 for Wound Healing - Drug Profile 186 Small Molecule for Chronic Wound Infection - Drug Profile 187 Small Molecule for Chronic Wounds and Burns - Drug Profile 188 Small Molecule for Wound Healing - Drug Profile 189 Small Molecule for Wounds - Drug Profile 190 Small Molecule to Inhibit MMP-1 and MMP-13 for Wounds - Drug Profile 191 Small Molecule to Target LGR6 for Wound Repair and Formation of New Hair Follicles - Drug Profile 192 Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile 193 Soluble Beta Glucan - Drug Profile 194 Stem Cell Therapy for Wound Healing - Drug Profile 197 Stem Cell Therapy for Wounds - Drug Profile 198 STP-705 - Drug Profile 199 StrataGraft Skin Tissue - Drug Profile 201 Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile 203 V-2248 - Drug Profile 205 Vasculotide - Drug Profile 207 Vernex - Drug Profile 208 XEN-103 - Drug Profile 209 Wounds - Recent Pipeline Updates 210 Wounds - Dormant Projects 225 Wounds - Discontinued Products 230 Wounds - Product Development Milestones 231 Featured News & Press Releases 231 Appendix 239 Methodology 239 Coverage 239 Secondary Research 239 Primary Research 239 Expert Panel Validation 239 Contact Us 240 Disclaimer 240
List of Tables Number of Products under Development for Wounds, H2 2014 18 Number of Products under Development for Wounds - Comparative Analysis, H2 2014 19 Number of Products under Development by Companies, H2 2014 21 Number of Products under Development by Companies, H2 2014 (Contd..1) 22 Number of Products under Development by Companies, H2 2014 (Contd..2) 23 Number of Products under Development by Companies, H2 2014 (Contd..3) 24 Number of Products under Development by Companies, H2 2014 (Contd..4) 25 Number of Products under Investigation by Universities/Institutes, H2 2014 27 Comparative Analysis by Late Stage Development, H2 2014 28 Comparative Analysis by Clinical Stage Development, H2 2014 29 Comparative Analysis by Early Stage Development, H2 2014 30 Comparative Analysis by Unknown Stage Development, H2 2014 31 Products under Development by Companies, H2 2014 32 Products under Development by Companies, H2 2014 (Contd..1) 33 Products under Development by Companies, H2 2014 (Contd..2) 34 Products under Development by Companies, H2 2014 (Contd..3) 35 Products under Development by Companies, H2 2014 (Contd..4) 36 Products under Investigation by Universities/Institutes, H2 2014 37 Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 38 Wounds - Pipeline by Advancell, H2 2014 39 Wounds - Pipeline by Aerpio Therapeutics, Inc., H2 2014 40 Wounds - Pipeline by AlgiPharma AS, H2 2014 41 Wounds - Pipeline by AndroScience Corporation, H2 2014 42 Wounds - Pipeline by AnGes MG, Inc., H2 2014 43 Wounds - Pipeline by APEIRON Biologics AG, H2 2014 44 Wounds - Pipeline by Apricus Biosciences, Inc., H2 2014 45 Wounds - Pipeline by Aridis Pharmaceuticals LLC, H2 2014 46 Wounds - Pipeline by Beech Tree Labs, Inc., H2 2014 47 Wounds - Pipeline by Bio3 Research S.r.l, H2 2014 48 Wounds - Pipeline by Biotec Pharmacon ASA, H2 2014 49 Wounds - Pipeline by Birken AG, H2 2014 50 Wounds - Pipeline by Blueberry Therapeutics Ltd, H2 2014 51 Wounds - Pipeline by CYATHUS EXQUIRERE PharmaforschungsGmbH, H2 2014 52 Wounds - Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2014 53 Wounds - Pipeline by Escape Therapeutics, Inc., H2 2014 54 Wounds - Pipeline by GangaGen Inc., H2 2014 55 Wounds - Pipeline by Garnet BioTherapeutics, H2 2014 56 Wounds - Pipeline by Gene Signal International SA, H2 2014 57 Wounds - Pipeline by GliaMed, Inc., H2 2014 58 Wounds - Pipeline by HanAll Biopharma Co., Ltd., H2 2014 59 Wounds - Pipeline by Hemostemix Ltd, H2 2014 60 Wounds - Pipeline by Juventas Therapeutics, Inc., H2 2014 61 Wounds - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 62 Wounds - Pipeline by Kasiak Research Pvt. Ltd., H2 2014 63 Wounds - Pipeline by Kuros Biosurgery AG, H2 2014 64 Wounds - Pipeline by Living Cell Technologies Limited, H2 2014 65 Wounds - Pipeline by MediWound Ltd., H2 2014 66 Wounds - Pipeline by Microbion Corporation, H2 2014 67 Wounds - Pipeline by miRagen Therapeutics, Inc., H2 2014 68 Wounds - Pipeline by Molecular Design International, Inc., H2 2014 69 Wounds - Pipeline by Nabriva Therapeutics AG, H2 2014 70 Wounds - Pipeline by NeoStem, Inc., H2 2014 71 Wounds - Pipeline by Neumedicines Inc., H2 2014 72 Wounds - Pipeline by Novan, Inc., H2 2014 73 Wounds - Pipeline by Nuvo Research Inc., H2 2014 74 Wounds - Pipeline by Octapharma AG, H2 2014 75 Wounds - Pipeline by Omeros Corporation, H2 2014 76 Wounds - Pipeline by Omnio Healer AB, H2 2014 77 Wounds - Pipeline by Pacific Northwest Biotechnology, LLC, H2 2014 78 Wounds - Pipeline by Pergamum AB, H2 2014 79 Wounds - Pipeline by Pharming Group N.V., H2 2014 80 Wounds - Pipeline by Regenics AS, H2 2014 81 Wounds - Pipeline by RXi Pharmaceuticals Corporation, H2 2014 82 Wounds - Pipeline by Sanofi, H2 2014 83 Wounds - Pipeline by Sirnaomics, Inc., H2 2014 84 Wounds - Pipeline by Smith & Nephew Plc, H2 2014 85 Wounds - Pipeline by SomaGenics Inc., H2 2014 86 Wounds - Pipeline by Stratatech Corporation, H2 2014 87 Wounds - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2014 88 Wounds - Pipeline by Theravasc, Inc., H2 2014 89 Wounds - Pipeline by Thesan Pharmaceuticals, Inc., H2 2014 90 Wounds - Pipeline by Tissue Repair Company, H2 2014 91 Wounds - Pipeline by vida therapeutics inc., H2 2014 92 Assessment by Monotherapy Products, H2 2014 93 Number of Products by Stage and Target, H2 2014 95 Number of Products by Stage and Mechanism of Action, H2 2014 98 Number of Products by Stage and Route of Administration, H2 2014 101 Number of Products by Stage and Molecule Type, H2 2014 103 Wounds Therapeutics - Recent Pipeline Updates, H2 2014 216 Wounds - Dormant Projects, H2 2014 231 Wounds - Dormant Projects (Contd..1), H2 2014 232 Wounds - Dormant Projects (Contd..2), H2 2014 233 Wounds - Dormant Projects (Contd..3), H2 2014 234 Wounds - Dormant Projects (Contd..4), H2 2014 235 Wounds - Discontinued Products, H2 2014 236
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
